Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 77,926 Shares

by · The Cerbat Gem

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) CEO Bradley Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $10.86, for a total transaction of $846,276.36. Following the completion of the transaction, the chief executive officer directly owned 1,129,782 shares in the company, valued at $12,269,432.52. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.11 during trading on Wednesday, reaching $11.00. 6,284,691 shares of the company were exchanged, compared to its average volume of 4,313,128. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -274.93 and a beta of 0.46. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The company has a 50-day moving average of $9.25 and a two-hundred day moving average of $7.72. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $11.14.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share. As a group, equities analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Institutional Trading of Amicus Therapeutics

Large investors have recently modified their holdings of the stock. Allworth Financial LP increased its stake in shares of Amicus Therapeutics by 36.3% in the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,246 shares in the last quarter. Allianz Asset Management GmbH increased its stake in Amicus Therapeutics by 0.3% in the third quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after purchasing an additional 1,333 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Amicus Therapeutics by 35.1% during the third quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,466 shares during the period. Parallel Advisors LLC boosted its position in shares of Amicus Therapeutics by 40.2% during the 3rd quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,649 shares in the last quarter. Finally, Gotham Asset Management LLC grew its stake in shares of Amicus Therapeutics by 1.5% in the 3rd quarter. Gotham Asset Management LLC now owns 138,523 shares of the biopharmaceutical company’s stock valued at $1,092,000 after buying an additional 1,987 shares during the period.

Analysts Set New Price Targets

Several research firms have recently issued reports on FOLD. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. The Goldman Sachs Group lifted their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Citigroup assumed coverage on shares of Amicus Therapeutics in a research report on Wednesday. They set a “buy” rating and a $17.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.29.

Check Out Our Latest Report on FOLD

About Amicus Therapeutics

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Further Reading